2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report
2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report
$2,995.00
Publisher: Datamonitor Healthcare
- Highlights
- Description
- Contents
The 71st Annual Meeting of the American Academy of Neurology (AAN) was held in Philadelphia, Pennsylvania, from May 4-10, 2019.
Conference highlights included movement in the rare disease space, namely pertaining to updated data in spinal muscular atrophy, early-phase data in amyotrophic lateral sclerosis, and pivotal data in neuromyelitis optica spectrum disorder. These were particularly noteworthy considering the lack of therapy options for these severe indications and the associated critical unmet need.
This post-meeting report features summaries of key topics alongside commentary from our team of expert analysts, which we highlight below. It also includes a compilation of all data events added in conjunction with the meeting.
Overview
The 71st Annual Meeting of the American Academy of Neurology (AAN) was held in Philadelphia, Pennsylvania, from May 4-10, 2019.
Conference highlights included movement in the rare disease space, namely pertaining to updated data in spinal muscular atrophy, early-phase data in amyotrophic lateral sclerosis, and pivotal data in neuromyelitis optica spectrum disorder. These were particularly noteworthy considering the lack of therapy options for these severe indications and the associated critical unmet need.
This post-meeting report features summaries of key topics alongside commentary from our team of expert analysts. It also includes a compilation of all data events added in conjunction with the meeting.
Contents
Meeting Overview – Key Indications……………………………………………………………………………………………….5
Amyotrophic Lateral Sclerosis (ALS) …………………………………………………………………………………………….5
Migraine ………………………………………………………………………………………………………………………………….5
Acute Migraine……………………………………………………………………………………………………………………..5
Chronic and Episodic Migraine………………………………………………………………………………………………..6
Neuromyelitis Optica Spectrum Disorder (NMOSD)……………………………………………………………………….6
Spinal Muscular Atrophy (SMA)…………………………………………………………………………………………………..7
Selected Abstracts Featured at AAN………………………………………………………………………………………………..9
Amyotrophic Lateral Sclerosis (ALS) …………………………………………………………………………………………….9
IONIS-SOD1Rx (BIIB, III) …………………………………………………………………………………………………………. 9
CK-2127107 (CYTK, Phase II)………………………………………………………………………………………………….11
Essential Tremor……………………………………………………………………………………………………………………..14
CX-8998 (Cavion, Phase II)…………………………………………………………………………………………………….14
Migraine and Other Headaches…………………………………………………………………………………………………17
Eptinezumab (ALDR, BLA)……………………………………………………………………………………………………..17
Eptinezumab (ALDR, BLA)……………………………………………………………………………………………………..20
Atogepant (AGN, III) …………………………………………………………………………………………………………….22
Ubrogepant (AGN, NDA)……………………………………………………………………………………………………….24
Rimegepant (BHVN, III)…………………………………………………………………………………………………………25
Emgality (LLY, Approved)………………………………………………………………………………………………………27
Emgality (LLY, Approved)………………………………………………………………………………………………………29
Myasthenia Gravis (MG)…………………………………………………………………………………………………………..31
Zilucoplan (RARX, II)……………………………………………………………………………………………………………..31
Neuromyelitis Optica (Devic’s syndrome, NMO)………………………………………………………………………….34
Soliris (ALXN, BLA) ……………………………………………………………………………………………………………….34
Satralizumab (RHHBY, III)………………………………………………………………………………………………………38
Inebilizumab (Viela, III)…………………………………………………………………………………………………………40
Parkinson’s Disease (PD)…………………………………………………………………………………………………………..42
DynaCirc (GSK, Investigator Initiated)……………………………………………………………………………………..42
Ongentys (NBIX, Phase III) …………………………………………………………………………………………………….44
VY-AADC (VYGR, Phase II)……………………………………………………………………………………………………..47
Seizure Disorders (Epilepsy) ……………………………………………………………………………………………………..50
Valtoco (Neurelis, NDA)………………………………………………………………………………………………………..50
Spinal Muscular Atrophy ………………………………………………………………………………………………………….51
Spinraza (BIIB, Approved)……………………………………………………………………………………………………..51
Spinraza (BIIB, Approved)……………………………………………………………………………………………………..53
Spinraza (BIIB, Approved)……………………………………………………………………………………………………..54
Zolgensma (NVS, BLA) ………………………………………………………………………………………………………….56
Zolgensma (NVS, BLA) ………………………………………………………………………………………………………….59
Zolgensma (NVS, BLA) ………………………………………………………………………………………………………….61
Zolgensma (NVS, BLA) ………………………………………………………………………………………………………….63
Risdiplam (RHHBY, III)…………………………………………………………………………………………………………..65
List of Biomedtracker AAN Events…………………………………………………………………………………………………70
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Hearing Aids Market US, 5EU Markets, Japan, and RoW 
Sign up to the